Emd Serono Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EMD SERONO, and when can generic versions of EMD SERONO drugs launch?
EMD SERONO has nine approved drugs.
There are thirteen US patents protecting EMD SERONO drugs.
There are one hundred and ninety-five patent family members on EMD SERONO drugs in forty-two countries and eighty-nine supplementary protection certificates in sixteen countries.
Summary for Emd Serono
| International Patents: | 195 |
| US Patents: | 13 |
| Tradenames: | 8 |
| Ingredients: | 7 |
| NDAs: | 9 |
Drugs and US Patents for Emd Serono
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emd Serono Inc | TEPMETKO | tepotinib hydrochloride | TABLET;ORAL | 214096-001 | Feb 3, 2021 | RX | Yes | Yes | 8,921,357 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Emd Serono Inc | TEPMETKO | tepotinib hydrochloride | TABLET;ORAL | 214096-001 | Feb 3, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Emd Serono Inc | GLUCOPHAGE XR | metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021202-004 | Apr 11, 2003 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Emd Serono Inc | TEPMETKO | tepotinib hydrochloride | TABLET;ORAL | 214096-001 | Feb 3, 2021 | RX | Yes | Yes | 8,329,692 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Emd Serono Inc | TEPMETKO | tepotinib hydrochloride | TABLET;ORAL | 214096-001 | Feb 3, 2021 | RX | Yes | Yes | 8,658,643 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Emd Serono
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Emd Serono Inc | GEREF | sermorelin acetate | INJECTABLE;INJECTION | 020443-002 | Sep 26, 1997 | 4,703,035 | ⤷ Try a Trial |
| Emd Serono | NOVANTRONE | mitoxantrone hydrochloride | INJECTABLE;INJECTION | 019297-001 | Dec 23, 1987 | 4,278,689 | ⤷ Try a Trial |
| Emd Serono Inc | MAVENCLAD | cladribine | TABLET;ORAL | 022561-001 | Mar 29, 2019 | 8,785,415 | ⤷ Try a Trial |
| Emd Serono Inc | MAVENCLAD | cladribine | TABLET;ORAL | 022561-001 | Mar 29, 2019 | 7,888,328 | ⤷ Try a Trial |
| Emd Serono Inc | CETROTIDE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 021197-001 | Aug 11, 2000 | 5,198,533 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Emd Serono Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2164843 | ⤷ Try a Trial |
| Slovenia | 2805723 | ⤷ Try a Trial |
| Canada | 3087419 | ⤷ Try a Trial |
| Brazil | PI0408848 | ⤷ Try a Trial |
| Japan | 2010532768 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Emd Serono Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1261586 | C01261586/02 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: SAXAGLIPTIN UND METFORMIN; NAT. REGISTRATION NO/DATE: SWISSMEDIC 62040 20120329 |
| 1506211 | 300677 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121 |
| 2164843 | PA2022009 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: TEPOTINIBAS IR FARMACINIU POZIURIU TINKAMI NAUDOTI JO SOLVATAI, DRUSKOS, TAUTOMERAI IR STEREOIZOMERAI ; REGISTRATION NO/DATE: EU/1/21/1596 20220216 |
| 1506211 | 132014902277722 | Italy | ⤷ Try a Trial | PRODUCT NAME: UNA COMBINAZIONE DI DAPAGLIFLOZIN O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE E METFORMINA O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE COME PROTETTI DAL BREVETTO DI BASE EP1506211(XIGDUO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/900, 20140116 |
| 1827461 | CR 2018 00010 | Denmark | ⤷ Try a Trial | PRODUCT NAME: CLADRIBINE; REG. NO/DATE: EU/1/17/1212 20170824 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
